2024-513033-21-00RecruitingPhase 1
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Source: EU CTIS (euclinicaltrials.eu) · Last updated 14 Aug 2026
Brief summary (registry, in English)
To monitor participants for delayed AEs associated with administration of autologous cells that have been genetically modified.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (estimated)
- First submitted
- 12 Jun 2024
- Start date
- 14 Sept 2020
- Lead sponsor
- USWM Ct LLC
- Diseases
- Childhood cancers, Multiple myeloma, Sarcoma, Lung cancer
- EU CT number
- 2024-513033-21-00
- EudraCT number
- 2018-004888-31
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 7
- 4 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who have already received at least one dose of an ADP cell therapy and finished or left an earlier ADP study or access program. They are followed over time for late side effects.
- Sex
- Women and men can join.
- Earlier treatment
- Must have received at least one dose of an ADP adoptive cell therapy. Must have completed or withdrawn from an ADP-sponsored or supported study, or completed treatment through managed access to an adoptive cell therapy.
Main reasons for not taking part
- The record lists no exclusion criteria.
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Participants who have received at least one dose of ADP adoptive cell therapy agent.
- Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
- Participants who have completed treatment as part of managed access to an adoptive cell therapy.
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- The investigator is responsible for review of medical history.
- Capable of giving signed informed consent.
Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Virgen Del Rocio S.L. | Sevilla | Spain | Recruiting |
| Centre Hospitalier Universitaire de Bordeaux | Pessac | France | Not yet recruiting |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Recruiting |
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Amsterdam | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.